Lead Product(s): SOTALOL HCI
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Deal Size: $69.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 26, 2020
This significant raise will support Hyloris’ strategy and will be used for the development of existing portfolio of product candidates, establishment of a commercial team in the United States, to fund the expansion of the pipeline, as well as for general corporate purposes.